Q2 2018
2018 Q2 results - Wednesday, July 18, 2018
Media release
Interim financial report (PDF 0.5 MB)
Read the presentation transcript
Download the presentation (PDF 1.8 MB)
Download the podcast (MP3 93 MB)
| Key figures1 | Q2 2018 (USD m) |
Q2 2017 (USD m) |
% change (USD/cc) |
|---|---|---|---|
| Net sales | 13,158 | 12,242 | 7 (cc: 5) |
| Operating income | 2,484 | 2,280 | 9 (cc: 6) |
| Net income | 7,768 | 1,979 | nm (cc: nm) |
| EPS (USD) | 3.34 | 0.84 | nm (cc: nm) |
| Free cash flow | 3,562 | 3,243 | 10 |
Core |
|||
| Operating income | 3,541 | 3,235 | 9 (cc: 7) |
| Net income | 3,011 | 2,866 | 5 (cc: 3) |
| EPS (USD) | 1.29 | 1.22 | 6 (cc: 4) |
- nm = not meaningful
- Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 54 of the Condensed Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.
Form 6-K Q2 2018
Documents Novartis results in line with requirements of the US Securities and Exchange Commission (SEC).
XBRL package Q2 2018
Documents Novartis results in XML format in line with requirements of the US Securities and Exchange Commission (SEC).